Optimizing Radiotherapy With Immunotherapy in Lung Cancer Treatment
This video examines how the use of radiation therapy in patients on immunotherapy can trigger immunogenic cell death, and reviews some of the challenges related to unwanted immune responses from radiotherapy.
Several reports have described how the use of radiation therapy in patients on immunotherapy can trigger immunogenic cell death.
In this video, Ramesh Rengan, MD, PhD, of the University of Washington in Seattle, highlights research aiming to optimize this combination of radiation therapy and immunotherapy, and discusses unwanted immune responses from radiotherapy and the challenge of utilizing this combination in patients with brain metastases.
Rengan gave a presentation on this topic at the 2017 Multidisciplinary Thoracic Cancers Symposium.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
